An Inactivated Novel Trivalent Vaccine Provides Complete Protection against FAdV-4 Causing Hepatitis-Hydropericardium Syndrome and FAdV-8b/-11 Causing Inclusion Body Hepatitis
Transboundary and Emerging Diseases · 22.02.2023 · 2023 · 1-13
DOI: 10.1155/2023/5122382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, erschienen am 22.02.2023. Verfasst von Congcong Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China. Hauptthemen laut MEDLINE: Chickens, Poultry Diseases, Viral Vaccines, Adenoviridae Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Outbreaks of hepatitis-hydropericardium syndrome (HHS) caused by fowl adenovirus serotype 4 (FAdV-4) and inclusion body hepatitis (IBH) related to FAdV-8b and FAdV-11 have been increased in chickens in China since 2015. Clinical concurrent infections of FAdV-4, FAdV-8b, and FAdV-11 are quite common, yet there are no commercially available trivalent vaccines against infection by these three serotypes. In our previous study, a bivalent vaccine based on a recombinant FAdV-4, of which fiber-1 was replaced with the fiber of FAdV-8b, has been developed. In this study, a novel recombinant rFAdV-4-fiber/8b + 11 was constructed by inserting FAdV-11 fiber gene into the 1966-bp deletion region of rFAdV-4-fiber/8b genome. The in vitro replication ability of the rFAdV-4-fiber/8b + 11 was similar to the parental FAdV-4. One dose immunization with the inactivated rFAdV-4-fiber/8b + 11 vaccine generated robust immune responses against FAdV-4, FAdV-8b, and FAdV-11, and provided efficient clinical protection against FAdV-4, FAdV-8b, and FAdV-11 challenge. This study provides a novel strategy for developing potential trivalent vaccines for the prevention and control of HHS and IBH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China.
- National Animal Health Products for Engineering Technology Research Center, Qingdao 266111, China.
ORCID-Profile: Jun Zhao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Song, C., Zhao, S., Song, M., Qiao, Q., Yang, P., Wang, B., Cong, Y., Wang, Y., Liu, H., Wang, Z., Wang, X., & Zhao, J. (2023). An Inactivated Novel Trivalent Vaccine Provides Complete Protection against FAdV-4 Causing Hepatitis-Hydropericardium Syndrome and FAdV-8b/-11 Causing Inclusion Body Hepatitis. Transboundary and Emerging Diseases, 2023, 1-13. https://doi.org/10.1155/2023/5122382
Vancouver
Song C, Zhao S, Song M, Qiao Q, Yang P, Wang B, et al. An Inactivated Novel Trivalent Vaccine Provides Complete Protection against FAdV-4 Causing Hepatitis-Hydropericardium Syndrome and FAdV-8b/-11 Causing Inclusion Body Hepatitis. Transboundary and Emerging Diseases. 2023;2023:1-13. doi:10.1155/2023/5122382
BibTeX
@article{Song2023,
author = {Song, Congcong and Zhao, Shiyi and Song, Mingzhen and Qiao, Qilong and Yang, Panpan and Wang, Baiyu and Cong, Yanfang and Wang, Yanling and Liu, Hongying and Wang, Zeng and Wang, Xinwei and Zhao, Jun},
title = {An Inactivated Novel Trivalent Vaccine Provides Complete Protection against FAdV-4 Causing Hepatitis-Hydropericardium Syndrome and FAdV-8b/-11 Causing Inclusion Body Hepatitis},
journal = {Transboundary and Emerging Diseases},
year = {2023},
volume = {2023},
pages = {1--13},
doi = {10.1155/2023/5122382}
}
EUVIMED